Q&A: Rademikibart may be ‘transformational therapy’ for moderate to severe asthma

Topline results from a phase 2b trial revealed that rademikibart led to improvements in lung function and asthma control in adults with moderate to severe persistent asthma compared with placebo.
In this global, multicenter, randomized, double-blind, placebo-controlled study, rademikibart (CBP-201, Connect BioPharma) was given to patients every 2 weeks for 24 weeks as either a 150 mg dose (n = 106) or a 300 mg dose (n = 108). The placebo group included 108 patients.
By week 12, patients receiving rademikibart had greater improvements in pre-bronchodilator FEV1 compared with patients receiving

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.